Genzyme Sues Over Endo's Bid To Sell Generic Renvela

Law360, New York (April 27, 2011, 8:24 PM EDT) -- Genzyme Corp. on Wednesday filed suit in Maryland accusing Endo Pharmaceuticals Inc. of infringing its patent covering Renvela by seeking approval to sell a generic version of the kidney disease treatment before the patent expires.

Genzyme claims Endo submitted an abbreviated new drug application to the U.S. Food and Drug Administration that infringes the claims of Genzyme's U.S. Patent No. 5,667,775, which covers phosphate-binding polymers for oral administration and is used to treat patients with chronic kidney disease on dialysis.

Genzyme has aggressively sought to protect...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.